Abstract:OBJECTIVE:To investigate the relationship between clinical features of patients with A/H5N1 infection and their prognosis in mainland China. METHODS:This study included 28 human cases with A/H5N1 infection in mainland China from October 2005 to May 2008. Data were collected and reviewed from hospital medical records and publishied papers. A database was built by EPIDATA 3.02 and statistical analyses were performed with SPSS 13.0. RESULTS:The median age of the 28 cases was 29 years (range 6-62), and 15 were females. Ten patients survived, and 18 died. The typically clinical manifestations of human influenza A/H5N1 infection included fever and lower respiratory infection. The numbers of peripheral white blood cells, lymphocytes and platelets in the survival and non-survival groups were (4.01 +/- 1.86) x 10(9)/L vs (5.1 +/- 2.9) x 10(9)/L, (1.09 +/- 0.49) x 10(9)/L vs (0.98 +/- 0.44) x 10(9)/L, and (116 +/- 39) x 10(9)/L vs (101 +/- 40) x 10(9)/L, respectively; the differences were not statistically significant between the 2 groups (P>0.05). There was also no statistically significant difference in the increased serum enzymes, such as aspartate aminotransferase [(173 +/- 246) U/L vs (272 +/- 263) U/L], lactate dehydrogenase [(1016 +/- 568) U/L vs (1512 +/- 1052) U/L], creatine kinase [(1099 +/- 1590) U/L vs (2534 +/- 4281) U/L] and MB isoenzyme of creatine kinase [(28 +/- 30) U/L vs (125 +/- 197) U/L] (P>0.05) between the survival and the non-survival groups. However, there was a statistically significant difference in the number of patients with an initial LDH level more than 8 fold of the normal value between the survival and the non-survival groups (none vs 6, P<0.05). All of the 28 cases developed bilateral multiple infiltrates and consolidation in chest radiographs. Acute respiratory distress syndrome occurred in 22 cases, 17 of them died. All the 9 patients with acute kidney injury died. Ten patients received antiviral treatment with oseltamivir, and 6 of them survived. There was a statistical difference in the time of initiating oseltamivir treatment between the survival and the non-survival cases [(6.5 +/- 3.0) d vs (11.8 +/- 3.3) d, Z = 3.70, P<0.05]. Broad spectrum antibiotics and corticosteroids were administered in all of the 28 cases. There was no statistical difference between the survival and the non-survival groups regarding to the corticosteroid treatment (P>0.05). CONCLUSIONS:Initial LDH level reaching more than 8 fold of the normal value suggests a poor prognosis for human H5N1 infection. Patients complicated with either ARDS or acute kidney injury had a higher risk of death. Early administration of effective antiviral agents might improve the prognosis and decrease case fatality.

Benefit of Early Initiation of Neuraminidase Inhibitor Treatment to Hospitalized Patients with Avian Influenza A(H7N9) Virus

Influenza A-associated Severe Pneumonia in Hospitalized Patients: Risk Factors and NAI Treatments.

The impact of early neuraminidase inhibitor therapy on clinical outcomes in patients hospitalised with influenza A-related pneumonia: a multicenter, retrospective study

Efficacy of oseltamivir-peramivir combination therapy compared to oseltamivir monotherapy for Influenza A (H7N9) infection: a retrospective study

Factors Associated with Prolonged Viral Shedding in Patients with Avian Influenza A(H7N9) Virus Infection

Impact of Early Neuraminidase Inhibitor Treatment on Clinical Outcomes in Patients with Influenza B-related Pneumonia: a Multicenter Cohort Study.

Neutrophil-lymphocyte ratio as an early new marker in AIV-H7N9-infected patients: a retrospective study.

Early antiviral therapy of abidor combined with lopinavir/ritonavir and re combinant interferonα 2b in patients with novel coronavirus pneumonia in Zhejiang: A multicenter and prospective study

Clinical findings in 111 cases of influenza A (H7N9) virus infection.

The need for strengthening the influenza virus detection ability of hospital clinical laboratories: an investigation of the 2009 pandemic

Adjuvant Corticosteroid Treatment in Adults with Influenza A (H7N9) Viral Pneumonia.

[Relationship Between Clinical Features and Prognosis of Highly Pathogenic Avian Influenza A/H5N1 Infection in Humans in Mainland China].

Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness among Patients Hospitalized with Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection

Clinical, virological, and histopathological manifestations of fatal human infections by avian influenza A(H7N9) virus.

Avian influenza A H7N9 virus induces severe pneumonia in mice without prior adaptation and responds to a combination of zanamivir and COX-2 inhibitor.

Antiviral Therapy And Outcomes Of Patients With Pneumonia Caused By Influenza A Pandemic (H1n1) Virus

The Protective Effects of the A/ZJU01/ PR8/2013 Split H7N9 Avian Influenza Vaccine Against Highly Pathogenic H7N9 in BALB/c Mice.

Evaluation of Plasma Exchange and Continuous Veno‐Venous Hemofiltration for the Treatment of Severe Avian Influenza <scp>A</scp> (<scp>H7N9</scp>): A Cohort Study

Severe Infection with Avian Influenza A Virus is Associated with Delayed Immune Recovery in Survivors

Kinetics of serological responses in influenza A(H7N9)-infected patients correlate with clinical outcome in China, 2013.

The Therapeutic Effect of Pamidronate on Lethal Avian Influenza A H7N9 Virus Infected Humanized Mice